1.47
-0.05 (-3.29%)
-0.05 (-3.29%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 46,175 |
|
|||||
| News | - | ||||||
| Day High | 1.59 | Low High |
|||||
| Day Low | 1.39 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Oncorus Inc | ONCR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.05 | -3.29% | 1.47 | 16:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.55 | 1.39 | 1.59 | 1.47 | 1.52 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 488 | 46,175 | $ 1.50 | $ 69,258 | - | 0.9827 - 14.12 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:58:21 | formt | 175 | $ 1.47 | USD |
Period:
Draw Mode:
Oncorus Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 38.18M | 25.97M | 20.00M | $ - | $ - | -2.55 | -0.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 386.50k | 2.00% |
Oncorus News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONCR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.34 | 1.65 | 1.29 | 1.52 | 64,168 | 0.13 | 9.7% |
| 1 Month | 1.32 | 1.65 | 1.20 | 1.39 | 53,284 | 0.15 | 11.36% |
| 3 Months | 1.17 | 1.90 | 0.9827 | 1.50 | 210,731 | 0.30 | 25.64% |
| 6 Months | 3.05 | 3.10 | 0.9827 | 1.60 | 171,832 | -1.58 | -51.8% |
| 1 Year | 13.37 | 14.12 | 0.9827 | 4.17 | 165,592 | -11.90 | -89.01% |
| 3 Years | 15.50 | 37.8603 | 0.9827 | 10.23 | 157,752 | -14.03 | -90.52% |
| 5 Years | 15.50 | 37.8603 | 0.9827 | 10.23 | 157,752 | -14.03 | -90.52% |
Oncorus Description
| Oncorus Inc is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-177; ONCR-GBM; Coxsackievirus A21 and Seneca Valley Virus. |